Clinical Trial Update: Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing TQ-B3139 to crizotinib in first-line ALK-positive non-small cell lung cancer is underway but results are not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• TQ-B3139

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: ALK-positive NSCLC | Phase 3 | Status: UNKNOWN